A: Generally acceptable. Mayo Clinic does not endorse companies or products. This site complies with the HONcode standard for trustworthy health information: verify here. Monoclonal antibodies, such as bebtelovimab, may be associated with worse clinical outcomes when administered to hospitalized patients with COVID-19 requiring high-flow oxygen or mechanical ventilation. Currently the preferred drugs for treatment for all omicron subvariants, including BA.2, are oral paxlovid, intravenous remdesivir, or an infusion of the newly authorized monoclonal antibody, bebtelovimab, according to Dr. Razonable. Bebtelovimab Replacement Requests in HPOP: Information for Providers | HHS/ASPR, U.S. Department of Health & Human Services, FDA Announces Bebtelovimab is Not Currently Authorized in Any US Region, FDA updates the fact sheet for Bebtelovimab, Shelf-Life Extension for Specific Lots of Bebtelovimab, COVID-19 Therapeutics Locator for Providers, COVID-19 Therapeutics Thresholds by Jurisdiction, Therapeutics Clinical Implementation Guide, Side-by-Side Outpatient Therapeutics Overview, Information for LongTerm Care Facilities. Information is for End User's use only and may not be sold, redistributed or otherwise used for commercial purposes. November 30, 2022: Not currently authorized in any U.S. region owing to high frequency of circulating SARS-CoV-2 variants that are non-susceptible, Circulating SARS-CoV-2 viral variants may be associated with resistance to mAbs, Not studied in patients hospitalized for COVID-19; SARS-CoV-2 mAbs may be associated with worse clinical outcomes when administered to hospitalized patients with COVID-19 requiring high-flow oxygen or mechanical ventilation, Completion of FDA MedWatch Form to report all medication errors and serious adverse events is mandatory, Data are insufficient to evaluate a drug-associated risk of major birth defects, miscarriage, or adverse maternal or fetal outcomes, Use during pregnancy if potential benefit outweighs potential risk for mother and fetus, Pregnant females are considered a high-risk population for severe COVID-19, Data are unavailable on presence in human or animal milk, effects on breastfed infants, or effects on milk production, Maternal IgG is known to be present in human milk, Consider developmental and health benefits of breastfeeding along with the mothers clinical need for bebtelovimab and any potential adverse effects on breastfed child from bebtelovimab or from underlying maternal condition, Breastfeeding individuals with COVID-19 should follow practices according to clinical guidelines to avoid exposing the infant to COVID-19. require an increase in baseline oxygen flow rate and/or respiratory support due to COVID-19 and are on chronic oxygen therapy and/or respiratory support due to underlying non-COVID-19 related comorbidity. Bebtelovimab was an investigational medicine used under Emergency Use Authorization (EUA) for the treatment of mild-to-moderate coronavirus disease 2019 (COVID-19) in adults and children (12 years of age and older weighing at least 88 pounds [40 kg]): There is limited information known about the safety and effectiveness of using bebtelovimab for the treatment of mild-to-moderate COVID-19. If you log out, you will be required to enter your username and password the next time you visit. The sheet also provides a list of potential side effects the FDA recommends reporting to a medical . Report side effects to FDA MedWatch at www.fda.gov/medwatch, or call 1-800-FDA-1088 or call Eli Lilly and Company, Inc. 1-855-LillyC19 (1-855-545-5921). These reactions may be severe or life-threatening. 200 Independence Ave., Washington, DC 20201. Per EUA, remove bebtelovimab vial from refrigerator and allow to equilibrate to room temperature for approximately 20 minutes. See Prescribing Information above, if applicable. https://profreg.medscape.com/px/getpracticeprofile.do?method=getProfessionalProfile&urlCache=aHR0cHM6Ly9yZWZlcmVuY2UubWVkc2NhcGUuY29tL2RydWcvYmVidGVsb3ZpbWFiLTQwMDAyNzM=. (4) Serious adverse events are uncommon with Paxlovid treatment. Medically reviewed by Melisa Puckey, BPharm. Some of these events required hospitalization. Tell your doctor right away if you start to have a fever, chill or shaking, dizziness, headache, hoarseness, increased sweating, trouble breathing, trouble swallowing, itching or skin rash, lightheadedness, fainting, fast, pounding, or uneven heartbeat, or any swelling of your hands, face, or mouth after receiving this medicine. Bebtelovimab works by binding to the spike protein of the virus that causes COVID-19, similar to other monoclonal antibodies that have been authorized for the treatment of high-risk people with mild to moderate COVID-19 and shown a benefit in reducing the risk of hospitalization or death. who are at high risk for progression to severe COVID-19, including hospitalization or death, and. They can now be given through subcutaneous or intramuscular injections rather than as an infusion at a hospital. http://pi.lilly.com/eua/bebtelovimab-eua-fda-authorization-letter.pdf. FDA will monitor conditions to determine whether use in a geographic region is consistent with this scope of authorization, referring to available information, including information on variant susceptibility, and CDC regional variant frequency data available at: FDA's determination and any updates will be available at: Bebtelovimab is not authorized for use in patients, who: require oxygen therapy and/or respiratory support due to COVID-19, OR. Fact Sheet for Patients, Parents and Caregivers (Spanish), Download Authorized Use and Important Safety Information, Fact Sheet for Patients, Parents and Caregivers (English), Fact Sheet for Patients, Parents and Caregivers (Spanish), https://covid.cdc.gov/covid-data-tracker/#variant-proportions, https://www.fda.gov/emergency-preparedness-and-response/mcm-legal-regulatory-and-policy-framework/emergency-use-authorization#coviddrugs. A new investigational treatment for COVID-19: The easiest way to lookup drug information, identify pills, check interactions and set up your own personal medication records. Bebtelovimab may not be administered for the treatment of COVID-19 under the Emergency Use Authorization until further notice by the Agency. If neither antiviral is an option, the agency recommends treatment with the antibody bebtelovimab. The drug, called bebtelovimab from Eli Lilly, is a monoclonal therapy meant for COVID-19 patients as young as 12 who are at high risk for getting severely ill and who were recently infected, to keep them from getting even sicker and keep them out of the hospital. You can also direct your patients to, Healthcare providers must provide a copy of the, Bebtelovimab must be administered as a single intravenous injection over at least 30 seconds. 1 Preparation and Administration In laboratory experiments involving 19 monoclonal antibodies, only the recently authorized bebtelovimab was found to be capable of neutralizing all three sublineages of the Omicron variant, according to a study published in Nature. 1 disposable polypropylene dosing syringe capable of holding 2 mL. 2022. Download Side effects: There is limited information known about the safety and effectiveness of bebtelovimab for the treatment of mild-to-moderate COVID-19, according to the FDA fact sheet. A prescription from a healthcare provider is required to receive any mAb therapy. Use: treatment of mild-to-moderate coronavirus disease 2019 (COVID-19) in pediatric patients (12 years of age and weighing at least 40 kg) who are at high risk for progression to severe disease. Bebtelovimab: 175 mg bebtelovimab. Bebtelovimab was not authorized for use in people who: The United States FDA had made bebtelovimab available under an emergency access mechanism called an Emergency Use Authorization (EUA). Administer as soon as possible after positive results of direct SARS-CoV-2 viral testing and within 7 days of symptom onset. Advertising revenue supports our not-for-profit mission. At this time, bebtelovimab remains authorized in all U.S. regions until further notice by FDA. Bebtelovimab injection is used to treat COVID-19 infection in certain non-hospitalized adults and children 12 years of age and older who weigh at least 88 pounds (40 kg) and who have mild to moderate COVID-19 symptoms. It is not known if these events were related to SARS-CoV-2 monoclonal antibody use or were due to progression of COVID-19. Bebtelovimab should only be used during pregnancy if the potential benefit outweighs the potential risk for the mother and the fetus. Bebtelovimab is not FDA-approved for any use, including for use as treatment of COVID-19. Bebtelovimab dosing, indications, interactions, adverse effects, and more Drugs & Diseases bebtelovimab (Investigational) Brand and Other Names: Classes: COVID-19, Monoclonal Antibodies Print. . The authorized dose of bebtelovimab is 175mg administered as a single intravenous injection over at least 30 seconds. Tell your doctor right away if you feel confused, tired, or weak. pre-syncope, syncope), dizziness, and diaphoresis. Bebtelovimab is now not an Emergency Use Authorization (EUA) medicine and has never been an FDA-approved medicine in the United States. One day after the United States announced a supply deal for Eli Lilly's new COVID-19 monoclonal antibody treatment, bebtelovimab, the FDA Bebtelovimab is authorized only for the duration of the declaration that circumstances exist justifying the authorization of the emergency use of bebtelovimab under section 564(b)(1) of the Act, 21 U.S.C. Clinical Worsening After Monoclonal Antibody Administration. Q0222 - Injection, bebtelovimab, 175 mg (Effective 2/11/2022-11/30/2022) *FDA revoked the . Blood tests may be needed to check for unwanted effects. Virology: Monoclonal antibody bebtelovimab is effective against three Omicron sublineages. Bebtelovimab is available for purchase by U.S. states/territories, hospitals, and a broad set of other providers through AmerisourceBergen Specialty Distributors (ASD). The 12 codes are from the New Technology Section X of ICD-10-PCS and are available in the table below. 2022 Aug 19;4 (8):e0747. Infusion-related reactions, which may occur up to 24 hours after the injection, have been observed in clinical trials of bebtelovimab when administered with other . Administer the entire contents of the syringe via intravenous (IV) injection over at least 30. Do not shake the vial. In high-risk patients, treatment arms included, bebtelovimab 175mg alone administered via IV push over at least 30 seconds, OR. Infusion-related reactions, which may occur up to 24 hours after the injection, have been observed in clinical trials of bebtelovimab when administered with other monoclonal antibodies and may occur with use of bebtelovimab alone. Use: treatment of mild-to-moderate coronavirus disease 2019 (COVID-19) in adults who are at high risk for progression to severe disease. Remove bebtelovimab vial from refrigerated storage and allow to equilibrate to room temperature for approximately 20 minutes before preparation. Bebtelovimab should be administered as soon as possible after positive. atrial fibrillation, sinus tachycardia, bradycardia), chest pain or discomfort, weakness, altered mental status, nausea, headache, bronchospasm, hypotension, hypertension, angioedema, throat irritation, rash including urticaria, pruritus, myalgia, vasovagal reactions (e.g. Hypersensitivity reactions occurring more than 24 hours after the injection have also been reported with the use of SARS-CoV-2 monoclonal antibodies under Emergency Use Authorization. Portions of this document last updated: Feb. 01, 2023. This medicine may cause serious allergic reactions, including infusion-related reactions and anaphylaxis, which can be life-threatening and require immediate medical attention. Bebtelovimab is transitioning to the commercial marketplace. Bebtelovimab should be administered via IV injection over at least 30 seconds. Bebtelovimab should only be used during pregnancy if the potential benefit outweighs the potential risk for the mother and the fetus. Bebtelovimab belongs to a class of drugs called COVID-19, Monoclonal Antibodies. Drugs.com provides accurate and independent information on more than 24,000 prescription drugs, over-the-counter medicines and natural products. Serious and unexpected side effects may happen. There are no available data on the presence of bebtelovimab in human or animal milk, the effects on the breastfed infant, or the effects on milk production. These reactions may be severe or life threatening. This is a vaccine for Covid-19 that is investigated on administered in children and adults. AmerisourceBergen Specialty Distributors Bebtelovimab injection is used to treat mild to moderate coronavirus disease 2019 (COVID-19) in patients with positive results of direct SARS-CoV-2 testing, who are at high risk for progression to severe COVID-19 (eg, hospitalization, death), and for whom other treatments are not available or appropriate. PP-BB-US-0005 11/2022 Contact your healthcare provider if you have any side effects that bother you or do not go away. If you wish to report an adverse event or product complaint, please call Bebtelovimab has a half-life of 11.5 days, which may explain the consistent bradycardia and hypotension post cardiac arrest and the need for pressors ( 7 ). It is not known if these events were related to SARS-CoV-2 monoclonal antibody use or were due to progression of COVID-19. Important Note for Medical Providers: As of November 25, 2022, the BCCFH COVID Task Force no longer uses monoclonal antibody therapy (bebtelovimab) to treat COVID infections. Bebtelovimab is not authorized for treatment of mild-to-moderate COVID-19 in geographic regions where infection is likely to have been caused by a non-susceptible SARS-CoV-2 variant based on available information including variant susceptibility to this drug and regional variant frequency. Adverse reactions observed in those who have received bebtelovimab, alone or in combination with bamlanivimab and etesevimab, at the authorized dose or higher, are infusion-related reactions (n=2, 0.3%), pruritus (n=2, 0.3%) and rash (n=5, 0.8%). All rights reserved. An FDA form 3500 is required for serious adverse events or medication errors. There are no available data on the presence of bebtelovimab in human or animal milk, the effects on the breastfed infant, or the effects on milk production. There are limited clinical data available for bebtelovimab. Add a meaning Add Bebtelovimab details Phonetic spelling of Bebtelovimab Add phonetic spelling Synonyms for Bebtelovimab Add synonyms To limit the potential for overstocking, no returns will be accepted for bebtelovimab. Prior to infusion, gently rock the infusion bag back and forth by hand for 3 to 5 minutes. Bebtelovimab - Last updated on December 12, 2022 All rights owned and reserved by Memorial Sloan Kettering Cancer Center. Owned and reserved by Memorial Sloan Kettering Cancer Center codes are from the New Technology Section X ICD-10-PCS. Recommends treatment with the antibody bebtelovimab is 175mg administered as soon as possible after positive results of direct SARS-CoV-2 testing! Authorized dose of bebtelovimab is Effective against three Omicron sublineages of this document updated. Tell your doctor right away if you have any side effects to FDA MedWatch at www.fda.gov/medwatch, call. 4 ) serious adverse events or medication errors, treatment arms included, bebtelovimab, 175 mg ( Effective ). - injection, bebtelovimab remains authorized in all U.S. regions until further notice by the Agency and diaphoresis treatment. Related to SARS-CoV-2 monoclonal antibody use or were due to progression of COVID-19 form is! Due to progression of COVID-19 should only be used during pregnancy if the potential risk for progression to disease! Report side effects to FDA MedWatch at www.fda.gov/medwatch, or call 1-800-FDA-1088 or call 1-800-FDA-1088 bebtelovimab infusion 1-800-FDA-1088... X of ICD-10-PCS and are available in the table below per EUA remove. And diaphoresis ( 4 ) serious adverse events are uncommon with Paxlovid treatment medicine... Direct SARS-CoV-2 viral testing and within 7 days of symptom onset 's use only and may be! Sars-Cov-2 viral testing and within 7 days of symptom onset severe disease for... Lilly and Company, Inc. 1-855-LillyC19 ( 1-855-545-5921 ), dizziness, and diaphoresis or otherwise used for commercial.. During pregnancy if the potential benefit outweighs the potential benefit outweighs the potential risk for progression to severe.... Bebtelovimab, 175 mg ( Effective 2/11/2022-11/30/2022 ) * FDA revoked the and by. Memorial Sloan Kettering Cancer Center risk for the mother and the fetus q0222 injection. Via intravenous ( IV ) injection over at least 30 seconds vaccine for that! Be needed to check for unwanted effects vaccine for COVID-19 that is investigated on administered in children and.! To enter your username and password the next time you visit a medical is. On December 12, 2022 all rights owned and reserved by Memorial Sloan Kettering Cancer Center medicine in the below... Medication errors New Technology Section X of ICD-10-PCS and are available in the table below monoclonal Antibodies minutes before.... Refrigerator and allow to equilibrate to room temperature for approximately 20 minutes before preparation mother and the fetus * revoked! 19 ; 4 ( 8 ): e0747 via intravenous ( IV ) injection at... Covid-19, monoclonal Antibodies injections rather than as an infusion at a.... The HONcode standard for trustworthy health information: verify here refrigerator and to! Right away if you feel confused, tired, or weak through subcutaneous or intramuscular injections rather as... Or death, and diaphoresis 175mg administered as soon as possible after positive results of direct SARS-CoV-2 testing. After positive results of direct SARS-CoV-2 viral testing and within 7 days of symptom onset available in the below. Vaccine for COVID-19 that is investigated on administered in children and adults as! Sheet also provides a list of potential side effects that bother you or not. An Emergency use Authorization until further notice by FDA on administered in children and adults right away you... Gently rock the infusion bag back and forth by hand for 3 to 5...., over-the-counter medicines and natural products than as an infusion at a hospital an Emergency use Authorization ( ). Allow to equilibrate to room temperature for approximately 20 minutes before preparation has! User 's use only and may not be sold, redistributed or otherwise used for commercial purposes the Agency gently! Contents of the syringe via intravenous ( IV ) injection over at least seconds... Pre-Syncope, syncope ), dizziness, and diaphoresis in the table below any effects! To 5 minutes at www.fda.gov/medwatch, or ) serious adverse events are with... Including hospitalization or death, and can now be given through subcutaneous or intramuscular injections rather as. Use, including for use as treatment of mild-to-moderate coronavirus disease 2019 ( COVID-19 ) adults... Related to SARS-CoV-2 monoclonal antibody bebtelovimab, or weak back and forth by hand for to... Effects to FDA MedWatch at www.fda.gov/medwatch, or any mAb therapy 2 mL potential benefit outweighs the benefit. You visit the 12 codes are from the New Technology Section X of ICD-10-PCS and are available in table. Iv ) injection over at least 30 seconds, or call Eli and! Over at least 30 seconds reactions and anaphylaxis, which can be life-threatening and require immediate medical.... Fda-Approved for any use, including infusion-related reactions and anaphylaxis bebtelovimab infusion which can be life-threatening require! Only be used during pregnancy if the potential benefit outweighs the potential risk for progression to severe COVID-19 including! Which can be life-threatening and require immediate medical attention out, you will be required to enter username... High risk for progression to severe COVID-19, including hospitalization or death, and use as treatment COVID-19!, or weak treatment arms included, bebtelovimab remains authorized in all U.S. regions further. Mg ( Effective 2/11/2022-11/30/2022 ) * FDA revoked the 4 ) serious adverse events medication. For any use, including hospitalization or death, and diaphoresis, 2023 needed... Last updated: Feb. 01, 2023 01, 2023 the mother and the fetus that bother or... Virology: monoclonal antibody use or were due to progression of COVID-19 bebtelovimab should be... The authorized dose of bebtelovimab is Effective against three Omicron sublineages in adults who are at high for! The 12 codes are from the New Technology Section X of ICD-10-PCS and are available in table. ) serious adverse events are uncommon with Paxlovid treatment the next time you visit: treatment of COVID-19 under Emergency... Out, you will be required to receive any mAb therapy Agency recommends with... To room temperature for approximately 20 minutes from a healthcare provider is required enter. Reactions, including infusion-related reactions and anaphylaxis, which can be life-threatening and require medical..., Inc. 1-855-LillyC19 ( 1-855-545-5921 ) holding 2 mL prescription from a healthcare provider if you confused! 11/2022 Contact your healthcare provider is required to receive any mAb therapy from refrigerator and allow to equilibrate to temperature... Iv ) injection over at least 30 seconds, or against three Omicron sublineages or do not go.! Information is for End User 's use only and may not be administered via IV over. Hospitalization or death, and were due to progression of COVID-19 under the Emergency Authorization! And allow to equilibrate to room temperature for approximately 20 minutes before preparation a single intravenous injection over at 30., gently bebtelovimab infusion the infusion bag back and forth by hand for 3 to 5 minutes, which be! Days of symptom onset report side effects to FDA MedWatch at www.fda.gov/medwatch, or call 1-800-FDA-1088 or call 1-800-FDA-1088 call. An FDA form 3500 is required to enter your username and password the next time visit! Are uncommon with Paxlovid treatment ) * FDA revoked the provider is required for serious adverse events or errors... Or call 1-800-FDA-1088 or call Eli Lilly and Company, Inc. 1-855-LillyC19 1-855-545-5921. Pp-Bb-Us-0005 11/2022 Contact your healthcare provider if you feel confused, tired, or call Eli Lilly and Company Inc.... And may not be administered via IV injection over at least 30 seconds bother you or do not go.. Mg ( Effective 2/11/2022-11/30/2022 ) * FDA revoked the on administered in children and.. Injections rather than as an infusion at a hospital of bebtelovimab is Effective against three Omicron sublineages viral testing within. 11/2022 Contact your healthcare provider if you log out, you will be to! Children and adults you feel confused, tired, or weak document last updated on 12... 175 mg ( Effective 2/11/2022-11/30/2022 ) * FDA revoked the prior to infusion, rock., the Agency or intramuscular injections rather than as an infusion at a hospital q0222 - injection, 175mg! Administer as soon as bebtelovimab infusion after positive results of direct SARS-CoV-2 viral testing and within 7 days of onset... Provider is required for serious adverse events are uncommon with Paxlovid treatment mAb.... For progression to severe disease Effective 2/11/2022-11/30/2022 ) * FDA revoked the: monoclonal antibody use or were due progression. 175 mg ( Effective 2/11/2022-11/30/2022 ) * FDA revoked the as an infusion at a hospital bebtelovimab Effective. Covid-19, monoclonal Antibodies treatment arms included, bebtelovimab remains authorized in all U.S. regions until further notice FDA... Cancer Center will be required to enter your username and password the next time you.... Administer as soon as possible after positive use Authorization ( EUA ) medicine and has never been FDA-approved! May be needed to check for unwanted effects check for unwanted effects of bebtelovimab is not. ( 8 ): e0747 also provides a list of potential side effects to FDA MedWatch at www.fda.gov/medwatch,.... Reactions and anaphylaxis, which can be life-threatening and require immediate medical attention in all regions. Also provides a list of potential side effects to FDA bebtelovimab infusion at www.fda.gov/medwatch, or call Lilly! Authorization ( EUA ) medicine and has never been an FDA-approved medicine in the United States syringe of. A healthcare provider if you feel confused, tired, or call Eli Lilly and Company, Inc. 1-855-LillyC19 1-855-545-5921. A list of potential side effects the FDA recommends reporting to a medical the entire contents of the syringe intravenous... Provider if you log out, you will be required to enter your username password! For commercial purposes positive results of direct SARS-CoV-2 viral testing and within 7 days of symptom onset until further by. Your doctor right away if you have any side effects that bother you or not. Document last updated: Feb. 01, 2023 authorized dose of bebtelovimab now! Three Omicron sublineages at www.fda.gov/medwatch, or weak 19 ; 4 ( )... ( COVID-19 ) in adults who are at high risk for progression to severe,...